Literature DB >> 23251733

Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies.

Fernando Bermejo1, Javier P Gisbert.   

Abstract

5-aminosalicylic acid (5-ASA) and thiopurines (azathioprine and mercaptopurine) are the most common drugs used as a maintenance treatment for ulcerative colitis. A considerable proportion of these patients develop corticosteroid dependency, and thiopurines are the standard treatment in this scenario. Dual prescriptions of both thiopurines and 5-ASA are common practice in steroid-dependent ulcerative colitis, in an attempt to optimize the efficacy of therapy. On the one hand, the potential protective role of 5-ASA against colorectal cancer argues in favour of prescription of both medications. The possible synergism between the two drugs, because of the inhibition of thiopurine methyltransferase (TPMT) enzyme activity by 5-ASA, has been postulated as another justification for dual prescription. However, existing evidence does not support that this combined strategy is superior to monotherapy with thiopurines. On the other hand, in patients showing prolonged disease remission, the possibility of discontinuing maintenance treatment can be considered on an individualized basis. The high frequency of relapses after thiopurine withdrawal should always be taken into account, but the potential adverse effects of the medication also need to be considered. A properly indicated treatment with thiopurines may need to be continued for life in many patients.

Entities:  

Keywords:  azathioprine; mercaptopurine; mesalazine; salicylate; thiopurine; ulcerative colitis

Year:  2010        PMID: 23251733      PMCID: PMC3513861          DOI: 10.1177/2040622310374897

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  51 in total

1.  Colorectal cancer prevention in ulcerative colitis: a case-control study.

Authors:  J Eaden; K Abrams; A Ekbom; E Jackson; J Mayberry
Journal:  Aliment Pharmacol Ther       Date:  2000-02       Impact factor: 8.171

2.  Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?

Authors:  S Ghosh; R Chaudhary; M Carpani; R J Playford
Journal:  Gut       Date:  2006-01       Impact factor: 23.059

Review 3.  Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?

Authors:  B E Sands
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

Review 4.  5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.

Authors:  T P van Staa; T Card; R F Logan; H G M Leufkens
Journal:  Gut       Date:  2005-06-30       Impact factor: 23.059

5.  The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.

Authors:  A G Fraser; T R Orchard; D P Jewell
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

6.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

7.  Is maintenance therapy always necessary for patients with ulcerative colitis in remission?

Authors:  S Ardizzone; M Petrillo; V Imbesi; R Cerutti; S Bollani; G Bianchi Porro
Journal:  Aliment Pharmacol Ther       Date:  1999-03       Impact factor: 8.171

8.  Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease.

Authors:  O Dewit; R Vanheuverzwyn; J P Desager; Y Horsmans
Journal:  Aliment Pharmacol Ther       Date:  2002-01       Impact factor: 8.171

9.  Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease.

Authors:  H Xin; C Fischer; M Schwab; U Klotz
Journal:  Aliment Pharmacol Ther       Date:  2005-05-01       Impact factor: 8.171

10.  Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients.

Authors:  R G Farmer; K A Easley; G B Rankin
Journal:  Dig Dis Sci       Date:  1993-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.